JP2015523546A - 失明性疾患を処置および診断するための方法 - Google Patents

失明性疾患を処置および診断するための方法 Download PDF

Info

Publication number
JP2015523546A
JP2015523546A JP2015509271A JP2015509271A JP2015523546A JP 2015523546 A JP2015523546 A JP 2015523546A JP 2015509271 A JP2015509271 A JP 2015509271A JP 2015509271 A JP2015509271 A JP 2015509271A JP 2015523546 A JP2015523546 A JP 2015523546A
Authority
JP
Japan
Prior art keywords
subject
disease
eye
compound
faf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015509271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523546A5 (US07585860-20090908-C00112.png
Inventor
ロメイン ボイド，シェリー
ロメイン ボイド，シェリー
Original Assignee
トランスレイタム メディカス インコーポレイテッド
トランスレイタム メディカス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トランスレイタム メディカス インコーポレイテッド, トランスレイタム メディカス インコーポレイテッド filed Critical トランスレイタム メディカス インコーポレイテッド
Publication of JP2015523546A publication Critical patent/JP2015523546A/ja
Publication of JP2015523546A5 publication Critical patent/JP2015523546A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2015509271A 2012-05-01 2013-04-30 失明性疾患を処置および診断するための方法 Pending JP2015523546A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261640854P 2012-05-01 2012-05-01
US61/640,854 2012-05-01
US201261641393P 2012-05-02 2012-05-02
US61/641,393 2012-05-02
US201261693226P 2012-08-24 2012-08-24
US61/693,226 2012-08-24
US201361792436P 2013-03-15 2013-03-15
US61/792,436 2013-03-15
PCT/CA2013/050335 WO2013163758A1 (en) 2012-05-01 2013-04-30 Methods for treating and diagnosing blinding eye diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017028425A Division JP2017114894A (ja) 2012-05-01 2017-02-17 失明性疾患を処置および診断するための方法

Publications (2)

Publication Number Publication Date
JP2015523546A true JP2015523546A (ja) 2015-08-13
JP2015523546A5 JP2015523546A5 (US07585860-20090908-C00112.png) 2016-06-16

Family

ID=49514154

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015509271A Pending JP2015523546A (ja) 2012-05-01 2013-04-30 失明性疾患を処置および診断するための方法
JP2017028425A Pending JP2017114894A (ja) 2012-05-01 2017-02-17 失明性疾患を処置および診断するための方法
JP2019125032A Active JP6837522B2 (ja) 2012-05-01 2019-07-04 失明性疾患を処置および診断するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017028425A Pending JP2017114894A (ja) 2012-05-01 2017-02-17 失明性疾患を処置および診断するための方法
JP2019125032A Active JP6837522B2 (ja) 2012-05-01 2019-07-04 失明性疾患を処置および診断するための方法

Country Status (9)

Country Link
EP (2) EP2844250B1 (US07585860-20090908-C00112.png)
JP (3) JP2015523546A (US07585860-20090908-C00112.png)
CN (2) CN104334173B (US07585860-20090908-C00112.png)
AU (2) AU2013255050B2 (US07585860-20090908-C00112.png)
CA (2) CA3095012C (US07585860-20090908-C00112.png)
DK (1) DK2844250T3 (US07585860-20090908-C00112.png)
ES (1) ES2656292T3 (US07585860-20090908-C00112.png)
IL (3) IL235395A (US07585860-20090908-C00112.png)
WO (1) WO2013163758A1 (US07585860-20090908-C00112.png)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017165674A (ja) * 2016-03-15 2017-09-21 岐阜市 アフリベルセプトによる網膜保護作用
JP2019531817A (ja) * 2016-10-13 2019-11-07 トランスレイタム メディカス インコーポレイテッド 眼疾患の検出のためのシステム及び方法
WO2021171788A1 (ja) * 2020-02-28 2021-09-02 浜松ホトニクス株式会社 眼底画像処理方法、眼底画像処理装置、眼底画像処理プログラム、及びそのプログラムを記録する記録媒体

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
JP6625064B2 (ja) * 2014-05-15 2019-12-25 トランスレイタム メディカス インコーポレイテッド 眼障害を治療かつ診断するための組成物および方法
CA2989270A1 (en) * 2015-06-16 2016-12-22 Translatum Medicus, Inc. Compositions and methods for treating and diagnosing ocular disorders
CN115998417A (zh) * 2016-06-24 2023-04-25 鲁美斯Be有限公司 利用激光等效强脉冲光装置的选择性皮肤处理
KR20190090844A (ko) 2016-12-05 2019-08-02 더 잭슨 래보라토리 인간에서의 신경퇴화 및 녹내장에 대한 진단적 마커로서의 망막 및 시신경 내 지방 알갱이
US20210060017A1 (en) * 2018-02-27 2021-03-04 Shilpa Medicare Ltd Methotrexate ophthalmic solution
CN112004457B (zh) * 2018-04-18 2024-06-21 株式会社尼康 图像处理方法、程序、图像处理装置及眼科系统
JP7279712B2 (ja) * 2018-04-18 2023-05-23 株式会社ニコン 画像処理方法、プログラム、及び画像処理装置
CN109222890A (zh) * 2018-08-24 2019-01-18 微云（武汉）科技有限公司 一种眼睛健康情况确定方法、装置和存储介质
CN109585017B (zh) * 2019-01-31 2023-12-12 上海宝藤生物医药科技股份有限公司 一种年龄相关性黄斑变性的风险预测算法模型和装置
WO2020261158A1 (en) 2019-06-25 2020-12-30 Translatum Medicus Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
EP4110316A4 (en) * 2020-02-26 2024-08-28 Univ Case Western Reserve COMPOSITIONS AND METHODS FOR TREATING MISFOLDED PROTEIN OCULAR DISEASES
CN114099515A (zh) * 2021-12-27 2022-03-01 中山大学中山眼科中心 氨甲蝶呤在制备治疗视网膜色素变性的药物方面的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129843A1 (en) * 2009-05-08 2010-11-11 Cytopathfinder, Inc. Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders
WO2011149010A1 (ja) * 2010-05-27 2011-12-01 参天製薬株式会社 新規インダゾール誘導体またはその塩およびその製造中間体、ならびに、それを用いた網脈絡膜変性疾患の予防または治療剤、網脈絡膜変性疾患の治療方法、インダゾール誘導体またはその塩の使用
WO2011149012A1 (ja) * 2010-05-27 2011-12-01 参天製薬株式会社 イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤、網脈絡膜変性疾患の予防または治療方法、イソキノリンスルホニル誘導体またはその医薬的に許容される塩、ならびにその使用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4080325A (en) 1976-11-17 1978-03-21 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of methotrexate
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1230441B (it) 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DK0770397T3 (da) 1995-10-18 2004-08-09 Akzo Nobel Nv Newcastle disease viruskombinationsvaccine
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
EP1192137B1 (en) 1999-06-30 2013-10-23 Amgen Inc. Compounds for the modulation of ppar-gamma activity
US20030235584A1 (en) 2000-02-28 2003-12-25 Kloetzer William S. Method for preparing anti-MIF antibodies
DK1287364T3 (da) * 2000-04-29 2009-03-02 Univ Iowa Res Found Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
WO2002068386A2 (en) 2001-02-27 2002-09-06 The Johns Hopkins University Tools and methods for identifying ppar$g(d)-specific agonists and antagonists
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
NZ537301A (en) 2002-06-07 2006-06-30 Cortical Pty Ltd Therapeutic molecules and methods-1
WO2004069809A1 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
BRPI0512623A (pt) 2004-06-25 2008-03-25 Janssen Phamaceutica N V sal quaternário antagonista de ccr2
KR20070063562A (ko) 2004-09-28 2007-06-19 얀센 파마슈티카 엔.브이. 치환 디피페리딘 ｃｃｒ２ 길항제
JP4897690B2 (ja) * 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US8067415B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
CN101410107A (zh) 2005-12-21 2009-04-15 科蒂科股份有限公司 Mif抑制剂
US20070197590A1 (en) 2006-01-31 2007-08-23 Demong Duane E Substituted dipiperidine ccr2 antagonists
DE102006030382A1 (de) * 2006-06-29 2008-01-03 Carl Zeiss Meditec Ag Verfahren und Vorrichtung zur optischen Detektion am Auge
AU2009221089B2 (en) * 2008-03-07 2013-12-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40
AU2009225389A1 (en) 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treating inflammation
UY33164A (es) * 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
US8808687B2 (en) * 2010-07-12 2014-08-19 Mark Humayun Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129843A1 (en) * 2009-05-08 2010-11-11 Cytopathfinder, Inc. Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders
WO2011149010A1 (ja) * 2010-05-27 2011-12-01 参天製薬株式会社 新規インダゾール誘導体またはその塩およびその製造中間体、ならびに、それを用いた網脈絡膜変性疾患の予防または治療剤、網脈絡膜変性疾患の治療方法、インダゾール誘導体またはその塩の使用
WO2011149012A1 (ja) * 2010-05-27 2011-12-01 参天製薬株式会社 イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤、網脈絡膜変性疾患の予防または治療方法、イソキノリンスルホニル誘導体またはその医薬的に許容される塩、ならびにその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6016019824; ＧＡＺＺＡＮＩＧＡ，Ｓ．　ｅｔ　ａｌ: Ｊｏｕｒｎａｌ　ｏｆ　Ｉｎｖｅｓｔｉｇａｔｉｖｅ　Ｄｅｒｍａｔｏｌｏｇｙ Ｖｏｌ．１２７, 2007, ｐ．２０３１-２０４１ *
JPN6016019826; ＮＯＶＡＣＫ，Ｇ．Ｄ．　ｅｔ　ａｌ: Ａｎｎｕａｌ　Ｒｅｖｉｅｗ　ｏｆ　Ｐｈａｒｍａｃｏｌｏｇｙ　ａｎｄ　Ｔｏｘｉｃｏｌｏｇｙ Ｖｏｌ．４８, 2008, ｐ．６１-７８ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017165674A (ja) * 2016-03-15 2017-09-21 岐阜市 アフリベルセプトによる網膜保護作用
JP2019531817A (ja) * 2016-10-13 2019-11-07 トランスレイタム メディカス インコーポレイテッド 眼疾患の検出のためのシステム及び方法
US11610311B2 (en) 2016-10-13 2023-03-21 Translatum Medicus, Inc. Systems and methods for detection of ocular disease
JP7308144B2 (ja) 2016-10-13 2023-07-13 トランスレイタム メディカス インコーポレイテッド 眼疾患の検出のためのシステム及び方法
WO2021171788A1 (ja) * 2020-02-28 2021-09-02 浜松ホトニクス株式会社 眼底画像処理方法、眼底画像処理装置、眼底画像処理プログラム、及びそのプログラムを記録する記録媒体

Also Published As

Publication number Publication date
IL254995A0 (en) 2017-12-31
EP3338776A1 (en) 2018-06-27
CA2911041C (en) 2020-12-15
CN107050020A (zh) 2017-08-18
IL235395A (en) 2017-10-31
WO2013163758A1 (en) 2013-11-07
CN104334173A (zh) 2015-02-04
AU2013255050A1 (en) 2014-11-13
AU2016219703B2 (en) 2017-09-14
CA3095012C (en) 2023-02-07
EP2844250B1 (en) 2017-11-08
IL260714B (en) 2019-08-29
DK2844250T3 (en) 2018-01-08
JP2017114894A (ja) 2017-06-29
CN104334173B (zh) 2017-05-03
EP2844250A4 (en) 2015-11-18
ES2656292T3 (es) 2018-02-26
CA2911041A1 (en) 2013-11-07
CA3095012A1 (en) 2013-11-07
AU2013255050B2 (en) 2016-07-28
JP2019194230A (ja) 2019-11-07
EP2844250A1 (en) 2015-03-11
JP6837522B2 (ja) 2021-03-03
AU2016219703A1 (en) 2016-09-15
IL254995B (en) 2018-08-30

Similar Documents

Publication Publication Date Title
JP6837522B2 (ja) 失明性疾患を処置および診断するための方法
US11992534B2 (en) Methods for treating and diagnosing blinding eye diseases
JP6625064B2 (ja) 眼障害を治療かつ診断するための組成物および方法
CA2870353C (en) Compositions and methods for treating and diagnosing ocular disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160425

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20160425

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20160520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160831

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170217

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170414

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170616